journal
MENU ▼
Read by QxMD icon Read
search

Cancer

journal
https://www.readbyqxmd.com/read/28234426/cancer-cytopathology-2016-young-investigator-challenge-building-an-ultrasound-guided-fna-clinic-our-5-year-experience-from-project-to-practice
#1
Oana C Rafael, Melissa Klein, Melissa M Serbonich, Bhumika Vadalia, Kasturi Das, Cecilia E Gimenez
BACKGROUND: The authors' fine-needle aspiration (FNA) clinic opened in 2010, allowing cytopathologists to increase their proficiency and experience in FNA performance. Here, they report their 5-year experience. METHODS: The FNA clinic log book and the institution's database were retrospectively reviewed to record patients' demographics, the number of FNAs performed per year by each cytopathologist, the number of passes, rapid on-site evaluation (ROSE) and diagnosis, adequacy-diagnosis concordance, and follow-up histology when available...
February 24, 2017: Cancer
https://www.readbyqxmd.com/read/28222251/prognostic-methylation-markers-for-overall-survival-in-cytogenetically-normal-patients-with-acute-myeloid-leukemia-treated-on-swog-trials
#2
Xiaoyu Qu, Megan Othus, Jerry Davison, Yu Wu, Liying Yan, Soheil Meshinchi, Fabiana Ostronoff, Elihu H Estey, Jerry P Radich, Harry P Erba, Frederick R Appelbaum, Min Fang
BACKGROUND: Aberrant DNA methylation is known to occur in patients with acute myeloid leukemia (AML), whereas methylation signatures and prognostic markers have been proposed. The objective of the current study was to evaluate all CpG sites of the genome and identify prognostic methylation markers for overall survival in patients with AML with normal karyotype (AML-NK). METHODS: AML-NK samples from 7 SWOG trials were analyzed using a novel genome-wide approach called "CHARMcox" (comprehensive high-throughput array-based relative methylation analysis combined with the Cox proportional hazards model) controlling for known clinical covariates...
February 21, 2017: Cancer
https://www.readbyqxmd.com/read/28222244/breast-fna-biopsy-cytology-current-problems-and-the-international-academy-of-cytology-yokohama-standardized-reporting-system
#3
Andrew S Field
No abstract text is available yet for this article.
February 21, 2017: Cancer
https://www.readbyqxmd.com/read/28222220/meaningful-endpoints-for-therapies-approved-for-hematologic-malignancies
#4
B Douglas Smith, Amy E DeZern, Alex W Bastian, Brian G M Durie
BACKGROUND: Overall survival (OS) is considered the gold standard for determining treatment efficacy in oncology trials, but the relation between treatment and OS can be challenging to assess because of long study durations and the impact of subsequent therapies on outcome. Using OS can be particularly difficult for new therapies in hematologic malignancies (HMs). METHODS: This retrospective analysis was conducted to characterize the primary endpoints used to support US Food and Drug Administration (FDA) approvals for new drug or novel HM indications between January 2002 and July 2015...
February 21, 2017: Cancer
https://www.readbyqxmd.com/read/28222219/longitudinal-follow-up-of-adult-survivors-of-ewing-sarcoma-a-report-from-the-childhood-cancer-survivor-study
#5
Neyssa M Marina, Qi Liu, Sarah S Donaldson, Charles A Sklar, Gregory T Armstrong, Kevin C Oeffinger, Wendy M Leisenring, Jill P Ginsberg, Tara O Henderson, Joseph P Neglia, Marilyn A Stovall, Yutaka Yasui, R Lor Randall, David S Geller, Leslie L Robison, Kirsten K Ness
BACKGROUND: Ewing sarcoma survivors (ESSs) are at increased risk for treatment-related complications. The incidence of treatment-related morbidity and late mortality with aging is unknown. METHODS: This study reports survival probabilities, estimated with the Kaplan-Meier method, and the cumulative incidence of cause-specific mortality and chronic conditions among ESSs in the Childhood Cancer Survivor Study who were treated between 1970 and 1986. Piecewise exponential models were used to estimate relative rates (RRs) and 95% confidence intervals (CIs) for these outcomes...
February 21, 2017: Cancer
https://www.readbyqxmd.com/read/28222215/epstein-barr-virus-specific-adoptive-immunotherapy-for-recurrent-metastatic-nasopharyngeal-carcinoma
#6
Julian Huang, Mark Fogg, Lori J Wirth, Heather Daley, Jerome Ritz, Marshall R Posner, Fred C Wang, Jochen H Lorch
BACKGROUND: Early-stage and intermediate stage nasopharyngeal cancer (NPC) generally carry a good prognosis, but for patients with recurrent, metastatic disease, options are limited. In the current study, the authors present a phase 1/2 study to evaluate the efficacy of Epstein-Barr virus (EBV)-stimulated cytotoxic T-lymphocyte (EBV-CTL) immunotherapy in this patient population. METHODS: Screening for patients with active, recurrent, metastatic EBV-associated NPC began in February 2007, and the study was closed to accrual in January 2012...
February 21, 2017: Cancer
https://www.readbyqxmd.com/read/28221673/breast-cancer-prevention-strategies-in-lobular-carcinoma-in-situ-a-decision-analysis
#7
Stephanie M Wong, Natasha K Stout, Rinaa S Punglia, Ipshita Prakash, Yasuaki Sagara, Mehra Golshan
BACKGROUND: Women diagnosed with lobular carcinoma in situ (LCIS) have a 3-fold to 10-fold increased risk of developing invasive breast cancer. The objective of this study was to evaluate the life expectancy (LE) and differences in survival offered by active surveillance, risk-reducing chemoprevention, and bilateral prophylactic mastectomy among women with LCIS. METHODS: A Markov simulation model was constructed to determine average LE and quality-adjusted LE (QALE) gains for hypothetical cohorts of women diagnosed with LCIS at various ages under alternative risk-reduction strategies...
February 21, 2017: Cancer
https://www.readbyqxmd.com/read/28218808/financial-toxicity-in-cancer-care-edging-toward-solutions
#8
EDITORIAL
Daniel A Goldstein
No abstract text is available yet for this article.
February 20, 2017: Cancer
https://www.readbyqxmd.com/read/28218801/do-cancer-survivors-change-their-prescription-drug-use-for-financial-reasons-findings-from-a-nationally-representative-sample-in-the-united-states
#9
Zhiyuan Zheng, Xuesong Han, Gery P Guy, Amy J Davidoff, Chunyu Li, Matthew P Banegas, Donatus U Ekwueme, K Robin Yabroff, Ahmedin Jemal
BACKGROUND: There is limited evidence from nationally representative samples about changes in prescription drug use for financial reasons among cancer survivors in the United States. METHODS: The 2011 to 2014 National Health Interview Survey was used to identify adults who reported ever having been told they had cancer (cancer survivors; n = 8931) and individuals without a cancer history (n = 126,287). Measures of changes in prescription drug use for financial reasons included: 1) skipping medication doses, 2) taking less medicine, 3) delaying filling a prescription, 4) asking a doctor for lower cost medication, 5) buying prescription drugs from another country, and 6) using alternative therapies...
February 20, 2017: Cancer
https://www.readbyqxmd.com/read/28211941/upfront-window-vincristine-irinotecan-treatment-of-high-risk-hepatoblastoma-a-report-from-the-children-s-oncology-group-ahep0731-study-committee
#10
Howard M Katzenstein, Wayne L Furman, Marcio H Malogolowkin, Mark D Krailo, M Beth McCarville, Alexander J Towbin, Greg M Tiao, Milton J Finegold, Sarangarajan Ranganathan, Stephen P Dunn, Max R Langham, Eugene D McGahren, Carlos Rodriguez-Galindo, Rebecka L Meyers
BACKGROUND: The identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma. METHODS: Patients with newly diagnosed metastatic hepatoblastoma or those with a serum α-fetoprotein (AFP) level <100 ng/mL were eligible...
February 17, 2017: Cancer
https://www.readbyqxmd.com/read/28211939/allogeneic-hematopoietic-cell-transplantation-for-primary-refractory-acute-lymphoblastic-leukemia-a-report-from-the-acute-leukemia-working-party-of-the-ebmt
#11
Jiří Pavlů, Myriam Labopin, Anna K Zoellner, Ioanna Sakellari, Matthias Stelljes, Jürgen Finke, Renato Fanin, Gernot Stuhler, Boris V Afanasyev, Adrian J Bloor, Achilles Anagnostopoulos, Mohamad Mohty, Sebastian Giebel, Arnon Nagler
BACKGROUND: Patients with primary refractory acute lymphoblastic leukemia (PREF ALL) who fail to achieve a complete remission (CR) after ≥2 courses of chemotherapy have a dismal prognosis without undergoing allogeneic hematopoietic cell transplantation (HCT). To the authors' knowledge, there currently are no data regarding factors influencing transplantation outcomes. METHODS: The authors retrospectively studied outcomes of transplantation for cases of PREF ALL reported to European Society for Blood and Marrow Transplantation registry...
February 17, 2017: Cancer
https://www.readbyqxmd.com/read/28211937/patterns-of-computed-tomography-surveillance-in-survivors-of-colorectal-cancer-at-veterans-health-administration-facilities
#12
Amikar Sehdev, Eric A Sherer, Siu L Hui, Jingwei Wu, David A Haggstrom
BACKGROUND: Annual computed tomography (CT) scans are a component of the current standard of care for the posttreatment surveillance of survivors of colorectal cancer (CRC) after curative-intent resection. The authors conducted a retrospective study with the primary aim of assessing patient, physician, and organizational characteristics associated with the receipt of CT surveillance among veterans. METHODS: The Department of Veterans Affairs Central Cancer Registry was used to identify patients diagnosed with AJCC collaborative stage I to III CRC between 2001 and 2009...
February 17, 2017: Cancer
https://www.readbyqxmd.com/read/28211936/reduction-of-cyclophosphamide-dose-for-patients-with-subset-2-low-risk-rhabdomyosarcoma-is-associated-with-an-increased-risk-of-recurrence-a-report-from-the-soft-tissue-sarcoma-committee-of-the-children-s-oncology-group
#13
David O Walterhouse, Alberto S Pappo, Jane L Meza, John C Breneman, Andrea Hayes-Jordan, David M Parham, Timothy P Cripe, James R Anderson, William H Meyer, Douglas S Hawkins
BACKGROUND: Failure-free survival (FFS) and overall survival (OS) rates were found to improve on Intergroup Rhabdomyosarcoma Study (IRS) IV (IRS-IV) compared with IRS-III for patients with subset 2 (IRS stage 1, group III nonorbit or stage 3, group I/II) low-risk embryonal rhabdomyosarcoma with the addition of cyclophosphamide (total cumulative cyclophosphamide dose of 26.4 g/m(2) ) to the combination of vincristine and dactinomycin (VAC). The goal of Children's Oncology Group ARST0331 for subset 2 low-risk patients was to reduce the total cumulative cyclophosphamide dose without compromising FFS...
February 17, 2017: Cancer
https://www.readbyqxmd.com/read/28207157/coping-strategies-tailored-to-the-management-of-fear-of-recurrence-and-adaptation-for-e-health-delivery-the-fortitude-intervention
#14
Lynne I Wagner, Jenna Duffecy, Frank Penedo, David C Mohr, David Cella
No abstract text is available yet for this article.
February 16, 2017: Cancer
https://www.readbyqxmd.com/read/28199747/outcomes-in-patients-with-early-stage-breast-cancer-who-underwent-a-21-gene-expression-assay
#15
Carlos H Barcenas, Akshara Raghavendra, Arup K Sinha, Masood Pasha Syed, Limin Hsu, Modesto G Patangan, Mariana Chavez-MacGregor, Yu Shen, Gabriel H Hortobagyi, Vicente Valero, Sharon H Giordano, Naoto T Ueno, Debu Tripathy
BACKGROUND: Invasive disease-free survival (IDFS) rates are excellent in patients with breast cancer (BC) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), axillary lymph node-negative (LN-) tumors with a 21-gene expression assay recurrence score (RS) of 0 to 10. However, to the authors' knowledge, the outcomes among patients with an RS of 11 to 25 who are treated with endocrine therapy alone are unknown. METHODS: In this retrospective single-institution study, the authors described the characteristics of patients with HR+, HER2-, LN- BC who underwent a 21-gene expression assay...
February 15, 2017: Cancer
https://www.readbyqxmd.com/read/28199067/human-epididymis-protein-4-immunostaining-of-malignant-ascites-differentiates-cancer-of-m%C3%A3-llerian-origin-from-gastrointestinal-cancer
#16
Anna Stiekema, Koen K Van de Vijver, Henk Boot, Annegien Broeks, Catharina M Korse, Willemien J van Driel, Gemma G Kenter, Christianne A R Lok
BACKGROUND: An accurate diagnosis of cancer of Müllerian origin is required before the initiation of treatment. An overlap in clinical presentation and cytological, histological, or imaging studies with other nongynecological tumors does occur. Therefore, immunocytochemistry markers are used to determine tumor origin. Human epididymis protein 4 (HE4) is overexpressed in tissue of epithelial ovarian cancer (EOC). It has shown to be a sensitive and specific serum marker for EOC and to be of value for the differentiation between EOC and ovarian metastases of gastrointestinal origin...
February 15, 2017: Cancer
https://www.readbyqxmd.com/read/28199006/symptom-incidence-distress-cancer-related-distress-and-adherence-to-chemotherapy-among-african-american-women-with-breast-cancer
#17
Melissa K Yee, Susan M Sereika, Catherine M Bender, Adam M Brufsky, Mary C Connolly, Margaret Q Rosenzweig
BACKGROUND: There is a persistent racial survival disparity between African American (AA) and white women with breast cancer. There is evidence that symptom incidence, associated distress, and overall cancer-related distress may be unexplored, important contributing factors. The purpose of the current study was to: 1) describe and compare the number of chemotherapy-related symptoms and associated distress among AA women with breast cancer over the course of chemotherapy at 3 time points (at baseline before initiating chemotherapy, midpoint, and at the completion of chemotherapy); and 2) to describe the relationship between the number of chemotherapy-related symptoms and overall cancer distress compared with the ability to receive at least 85% of the prescribed chemotherapy within the prescribed timeframe...
February 15, 2017: Cancer
https://www.readbyqxmd.com/read/28195686/diagnosis-of-anaplastic-lymphoma-kinase-rearrangement-in-cytological-samples-through-a-fluorescence-in-situ-hybridization-based-assay-cytological-smears-versus-cell-blocks
#18
Federica Zito Marino, Giulio Rossi, Matteo Brunelli, Maria Gabriella Malzone, Giuseppina Liguori, Giuseppe Bogina, Alessandro Morabito, Gaetano Rocco, Renato Franco, Gerardo Botti
Anaplastic lymphoma kinase (ALK) status analysis of lung cytological specimens should be successfully encouraged in routine practice because biopsy specimens are not always available. To date, the US Food and Drug Administration has approved both fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) as diagnostic tests for identifying ALK-positive patients eligible for treatment with crizotinib. Although ALK IHC is an optimal diagnostic tool, FISH becomes mandatory in equivocal cases. ALK FISH of paraffin-embedded tissue material is still the gold standard, whereas the cytological specimen assay has not yet been completely standardized...
February 14, 2017: Cancer
https://www.readbyqxmd.com/read/28195651/early-estimates-of-seer-cancer-incidence-2014
#19
Denise Riedel Lewis, Huann-Sheng Chen, Myles G Cockburn, Xiao-Cheng Wu, Antoinette M Stroup, Douglas N Midthune, Zhaohui Zou, Martin F Krapcho, Daniel G Miller, Eric J Feuer
BACKGROUND: Cancer incidence rates and trends for cases diagnosed through 2014 using data reported to the Surveillance, Epidemiology, and End Results (SEER) program in February 2016 and a validation of rates and trends for cases diagnosed through 2013 and submitted in February 2015 using the November 2015 submission are reported. New cancer sites include the pancreas, kidney and renal pelvis, corpus and uterus, and childhood cancer sites for ages birth to 19 years inclusive. METHODS: A new reporting delay model is presented for these estimates for more consistent results with the model used for the usual November SEER submissions, adjusting for the large case undercount in the February submission...
February 14, 2017: Cancer
https://www.readbyqxmd.com/read/28195644/impact-of-the-elimination-of-cost-sharing-for-mammographic-breast-cancer-screening-among-rural-us-women-a-natural-experiment
#20
Jeffrey Peppercorn, Nora Horick, Kevin Houck, Julia Rabin, Victor Villagra, Gary H Lyman, Stephanie B Wheeler
BACKGROUND: Rural US women experience disparities in breast cancer screening and outcomes. In 2006, a national rural health insurance provider, the National Rural Electric Cooperative Association (NRECA), eliminated out-of-pocket costs for screening mammography. METHODS: This study evaluated the elimination of cost sharing as a natural experiment: it compared trends in screening before and after the policy change. NRECA insurance claims data were used to identify all women aged 40 to 64 years who were eligible for breast cancer screening, and mammography utilization from 1998 through 2011 was evaluated...
February 14, 2017: Cancer
journal
journal
20067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"